Trials / Unknown
UnknownNCT04407312
Cilostazol and Endothelial Progenitor Cell
Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients With Acute Myocardial Infarction: A Randomized, Placebo-controlled ACCEL-EPISODE Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Gyeongsang National University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)
Detailed description
Primary endpoint: % Change of EPC count Secondary endpoints: 1. Changes of ADP/AA/collagen-induced PFT 2. Changes of lipid profile and high sensitivity-C-reactive protein 3. Change of TEG measurements 4. Change of PWV 5. Predictors of EPC count (baseline and 1-month) 6. ischemic (CV death, MI \& stroke) and bleeding events (BARC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol Tablets | Cilostazol-SR, capsule, 200mg, once daily, 30 days. |
| DRUG | placebo | Placebo, tablet, 200mg, once daily, 30 days. |
| DRUG | Aspirin | Astrix, capsule,100mg, once daily, 30 days. |
| DRUG | Clopidogrel | Plavix, tablet, 75mg, once daily, 30 days. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-12-31
- Completion
- 2020-07-31
- First posted
- 2020-05-29
- Last updated
- 2020-05-29
Source: ClinicalTrials.gov record NCT04407312. Inclusion in this directory is not an endorsement.